00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
11:42 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Daprodustat: Ph III started

GlaxoSmithKline began the open-label, U.S. Phase III ASCEND-ND trial to compare oral daprodustat once daily vs. subcutaneous darbepoetin alfa in about 4,500 non-dialysis-dependent patients switching from, or are naïve to, an erythropoietin-stimulating agent (ESA). Patients...
11:42 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Daprodustat: Ph III started

GlaxoSmithKline began the open-label, U.S. Phase III ASCEND-D trial to compare oral daprodustat once daily vs. subcutaneous or IV darbepoetin alfa in about 3,000 dialysis patients switching from an erythropoietin-stimulating agent (ESA). Patients will have...
07:00 , Aug 12, 2013 |  BioCentury  |  Strategy

FibroGen's globetrotting

Seven years after its last major deal, FibroGen Inc. has now carved up worldwide rights to FG-4592 via its new deal with AstraZeneca plc . A key task for FibroGen is now to execute in...